Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 3/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.38 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.36 |
| ▸ | GCGR | P47871 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
| ▸ | RARB | P10826 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RARA | P10276 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3272113 | 0.92 | PLA2G4B (0.45) | MAPTSMN1; SMN2PLA2G4BXDHRARB | |
| SCHEMBL4276574 | 0.92 | PLA2G4B (0.45) | MAPTSMN1; SMN2PLA2G4BXDHRARB | |
| SCHEMBL4271615 | 0.90 | PLA2G4B (0.46) | MAPTSMN1; SMN2PLA2G4BXDHRARB | |
| SCHEMBL3271787 | 0.88 | MAPT (0.42) | MAPTSMN1; SMN2PDE4APDE4BPDE4C | |
| SCHEMBL12636637 | 0.87 | PLA2G4B (0.40) | MAPTSMN1; SMN2PLA2G4BXDHMEN1 | |
| SCHEMBL7171414 | 0.84 | PLA2G4B (0.44) | MAPTSMN1; SMN2PDE4APDE4BPDE4C | |
| SCHEMBL29382893 | 0.83 | PLA2G4B (0.52) | MAPTSMN1; SMN2PLA2G4BRARBKMT2A | |
| SCHEMBL4270500 | 0.83 | PLA2G4B (0.52) | MAPTSMN1; SMN2PLA2G4BRARBKMT2A | |
| SCHEMBL8924412 | 0.83 | PLA2G4B (0.52) | MAPTSMN1; SMN2PLA2G4BRARBKMT2A | |
| SCHEMBL8177795 | 0.82 | MAPT (0.41) | MAPTSMN1; SMN2PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100085531-A1 | LIQUID CRYSTAL MOLECULE, LIQUID CRYSTAL MATERIAL, LIQUID CRYSTAL DISPLAY DEVICE AND LIQUID CRYSTAL OPTICAL SPATIAL MODULATION DEVICE | SONY CORPORATION (JP) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100085531-A1 | LIQUID CRYSTAL MOLECULE, LIQUID CRYSTAL MATERIAL, LIQUID CRYSTAL DISPLAY DEVICE AND LIQUID CRYSTAL OPTICAL SPATIAL MODULATION DEVICE | CXCR1, CCR3, CXCR2 | MAPT 3500/4885SMN1; SMN2 4363/4885PDE4A 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.